Evidence map›Paper›PMID 42574620›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

An antisense method for efficient exon skipping and its application to Duchenne muscular dystrophy.

Pengchao Feng, Peng Gao, Shaodong Meng, Yunxia Yuan, Adrian R Krainer, Yimin Hua

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pengchao Feng *Nanjing Antisense Biopharm, Nanjing, Jiangsu 210023, China.
Peng Gao *Nanjing Antisense Biopharm, Nanjing, Jiangsu 210023, China.
Shaodong Meng *Nanjing Antisense Biopharm, Nanjing, Jiangsu 210023, China.
Yunxia YuanNanjing Antisense Biopharm, Nanjing, Jiangsu 210023, China.
Adrian R KrainerCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724.ORCID 0000-0001-9024-9501
Yimin HuaNanjing Antisense Biopharm, Nanjing, Jiangsu 210023, China.

Funding

BIOCHEMISTRY OF PREMRNA SPLICINGR01GM042699 · NIGMS · COLD SPRING HARBOR LABORATORY · PI Adrian R Krainer · 1989 to 2026
$8.8M
ASOcura Pharmaceuticals N/AHHS | NIH | National Institute of General Medical Sciences (NIGMS) R01 GM042699Nanjing Antisense Biopharm N/ANIGMS NIH HHS R01 GM042699St. Giles Foundation (St Giles Foundation) N/A
6 · The paper itself

Abstract

Antisense-mediated exon skipping has been used to treat Duchenne muscular dystrophy (DMD) by restoring the

Indexed as

DystrophinExonsMuscular Dystrophy, DuchenneOligonucleotides, AntisenseAnimalsGenetic TherapyHumansMiceMice, Inbred mdxRNA PrecursorsRNA, Small NuclearRNA Splice SitesRNA SplicingDystrophinOligonucleotides, AntisenseRNA PrecursorsRNA, Small NuclearRNA Splice SitesU1 small nuclear RNAbipartite antisense oligonucleotidesDuchenne muscular dystrophyexon skipping

Identifiers

PMID42574620
PMCPMC13486594

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.